Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model

Curtis A. Lachowiez, Joshua F. Zeidner, Jad Othman, Andy Kaempf, Seongseok Yun, Maël Heiblig, Michael Heuser, Rabia Shahswar, Rafael Madero Marroquin, Joseph M. Cannova, Andrius Žučenka, Jennifer Marvin-Peek, Jayastu Senapati, Yasmin Abaza, Alok Swaroop, Irene Zacheo, Federica Monaco, Amine Belhabri, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Martin Carré, Gaspar Aspas Requena, Rachel J. Cook, Elie Traer, Jennifer N. Saultz, Jenny O'Nions, Faisal Basheer, John Laurie, Shivani Handa, Eytan M. Stein, Maria R. Baer, Rebecca Olin, William Blum, Gary Schiller, Tara Lin, Emily Curran, Ashley Yocum, Ellen Madarang, Naval Daver, Tapan M. Kadia, Giovanni Marconi, Yazan Madanat, Richard Dillon, Courtney D. DiNardo, Ronan Swords, Juan E. Arango Ossa, Justin Watts, Sanam Loghavi, Daniel A. Pollyea, Elsa Bernard, Unknown, Anand A. Patel, Wendy Stock, Dimitrios Drekolias, Fatima Tuz Zahra, Nicola Long, Alok Swaroop, Ying Huang, Rina Li Welkie

Open source

DOI: 10.1200/jco-26-00347
Published: 2026-09-01
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-26-00347,
  title = {Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model},
  author = {Curtis A. Lachowiez and Joshua F. Zeidner and Jad Othman and Andy Kaempf and Seongseok Yun and Maël Heiblig and Michael Heuser and Rabia Shahswar and Rafael Madero Marroquin and Joseph M. Cannova and Andrius Žučenka and Jennifer Marvin-Peek and Jayastu Senapati and Yasmin Abaza and Alok Swaroop and Irene Zacheo and Federica Monaco and Amine Belhabri and Urbain Tauveron-Jalenques and Emmanuelle Tavernier and Martin Carré and Gaspar Aspas Requena and Rachel J. Cook and Elie Traer and Jennifer N. Saultz and Jenny O'Nions and Faisal Basheer and John Laurie and Shivani Handa and Eytan M. Stein and Maria R. Baer and Rebecca Olin and William Blum and Gary Schiller and Tara Lin and Emily Curran and Ashley Yocum and Ellen Madarang and Naval Daver and Tapan M. Kadia and Giovanni Marconi and Yazan Madanat and Richard Dillon and Courtney D. DiNardo and Ronan Swords and Juan E. Arango Ossa and Justin Watts and Sanam Loghavi and Daniel A. Pollyea and Elsa Bernard and Unknown and Anand A. Patel and Wendy Stock and Dimitrios Drekolias and Fatima Tuz Zahra and Nicola Long and Alok Swaroop and Ying Huang and Rina Li Welkie},
  year = {2026},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco-26-00347},
  url = {https://doi.org/10.1200/jco-26-00347}
}

RIS

TY  - JOUR
TI  - Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model
AU  - Curtis A. Lachowiez
AU  - Joshua F. Zeidner
AU  - Jad Othman
AU  - Andy Kaempf
AU  - Seongseok Yun
AU  - Maël Heiblig
AU  - Michael Heuser
AU  - Rabia Shahswar
AU  - Rafael Madero Marroquin
AU  - Joseph M. Cannova
AU  - Andrius Žučenka
AU  - Jennifer Marvin-Peek
AU  - Jayastu Senapati
AU  - Yasmin Abaza
AU  - Alok Swaroop
AU  - Irene Zacheo
AU  - Federica Monaco
AU  - Amine Belhabri
AU  - Urbain Tauveron-Jalenques
AU  - Emmanuelle Tavernier
AU  - Martin Carré
AU  - Gaspar Aspas Requena
AU  - Rachel J. Cook
AU  - Elie Traer
AU  - Jennifer N. Saultz
AU  - Jenny O'Nions
AU  - Faisal Basheer
AU  - John Laurie
AU  - Shivani Handa
AU  - Eytan M. Stein
AU  - Maria R. Baer
AU  - Rebecca Olin
AU  - William Blum
AU  - Gary Schiller
AU  - Tara Lin
AU  - Emily Curran
AU  - Ashley Yocum
AU  - Ellen Madarang
AU  - Naval Daver
AU  - Tapan M. Kadia
AU  - Giovanni Marconi
AU  - Yazan Madanat
AU  - Richard Dillon
AU  - Courtney D. DiNardo
AU  - Ronan Swords
AU  - Juan E. Arango Ossa
AU  - Justin Watts
AU  - Sanam Loghavi
AU  - Daniel A. Pollyea
AU  - Elsa Bernard
AU  - Unknown
AU  - Anand A. Patel
AU  - Wendy Stock
AU  - Dimitrios Drekolias
AU  - Fatima Tuz Zahra
AU  - Nicola Long
AU  - Alok Swaroop
AU  - Ying Huang
AU  - Rina Li Welkie
PY  - 2026
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-26-00347
UR  - https://doi.org/10.1200/jco-26-00347
ER  -

APA

Lachowiez, C. A., Zeidner, J. F., Othman, J., Kaempf, A., Yun, S., Heiblig, M., Heuser, M., Shahswar, R., Marroquin, R. M., Cannova, J. M., Žučenka, A., Marvin-Peek, J., Senapati, J., Abaza, Y., Swaroop, A., Zacheo, I., Monaco, F., Belhabri, A., Tauveron-Jalenques, U., Tavernier, E., Carré, M., Requena, G. A., Cook, R. J., Traer, E., Saultz, J. N., O'Nions, J., Basheer, F., Laurie, J., Handa, S., Stein, E. M., Baer, M. R., Olin, R., Blum, W., Schiller, G., Lin, T., Curran, E., Yocum, A., Madarang, E., Daver, N., Kadia, T. M., Marconi, G., Madanat, Y., Dillon, R., DiNardo, C. D., Swords, R., Ossa, J. E. A., Watts, J., Loghavi, S., Pollyea, D. A., Bernard, E., Unknown, Patel, A. A., Stock, W., Drekolias, D., Zahra, F. T., Long, N., Swaroop, A., Huang, Y., & Welkie, R. L. (2026). Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00347

Source records

crossref · retrieved 2026-09-25T06:45:42.513Z